Drug & intervention

acarbose

RxCUI 16681

Clinical trials42
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Acarbose

Acarbose (INN) is an anti-diabetic drug used to treat diabetes mellitus type 2 and (in some countries), prediabetes. It is sold in Europe and China as Glucobay (Bayer AG), in North America as Precose (Bayer Pharmaceuticals), and in Canada as Prandase (Bayer AG). Acarbose is a starch blocker that works by inhibiting alpha glucosidase, an intestinal enzyme that releases glucose from larger carbohydrates such as starch and sucrose. It is composed of an acarviosin moiety with a maltose at the reducing terminus. It can be degraded by gut bacteria. Acarbose is inexpensive and popular in China, but not in the U.S. One physician explains that U.S. use is limited, because it is not potent enough to offset side effects of diarrhea and flatulence. However, a large 2013 study reported that "acarbose is effective, safe and well tolerated in a large cohort of Asian patients with type 2 diabetes." One possible explanation for the differing claims is that acarbose is significantly more effective in patients eating a relatively high-starch, Eastern diet.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive ImpairmentNCT07711171 · 2024-08-19
RECRUITING
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 DiabetesNCT07122102 · 2025-10-01
NOT_YET_RECRUITING
Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 DiabetesNCT05629806 · 2022-04-10
UNKNOWN
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. AcarboseNCT04180813 · 2020-03-04
TERMINATED
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug NaiveNCT03794336 · 2019-06-29
COMPLETED
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 DiabetesNCT03602638 · 2018-10-01
UNKNOWN
Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.NCT03380546 · 2018-07-04
TERMINATED
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure PatientsNCT03349684 · 2018-03-05
COMPLETED
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin TherapyNCT03359837 · 2018-01-20
COMPLETED
A Phase IV Study in Drug-Naive Patients With T2DM in ChinaNCT03344341 · 2017-12-15
TERMINATED
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small IntestinesNCT03241303 · 2017-08-01
COMPLETED
Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 DiabetesNCT02605772 · 2015-12-01
UNKNOWN
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 DiabetesNCT02315495 · 2015-04-03
COMPLETED
the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix InsulinNCT02438397 · 2014-12-01
UNKNOWN
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM PatientsNCT02500329 · 2014-09-01
UNKNOWN
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin MonotherapyNCT02243176 · 2014-09-01
COMPLETED
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 DiabetesNCT02049814 · 2014-05-09
COMPLETED
Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes MellitusNCT02143765 · 2014-05-01
COMPLETED
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)NCT02072096 · 2014-02-01
TERMINATED
Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.NCT01839344 · 2013-05-01
COMPLETED
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 DiabetesNCT01758471 · 2012-12-01
UNKNOWN
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)NCT01709305 · 2012-11-08
COMPLETED
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes MellitusNCT01514838 · 2012-04-23
TERMINATED
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM PatientsNCT01490918 · 2012-04-01
COMPLETED
Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 DiabetesNCT01624116 · 2011-08-01
COMPLETED
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)NCT01177384 · 2011-01-25
COMPLETED
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)NCT01181674 · 2011-01-01
COMPLETED
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes MellitusNCT01245166 · 2010-11-01
UNKNOWN
Thiazolidinedione (TZD) on the Diabetic Retinopathy and NephropathyNCT01175486 · 2010-07-01
UNKNOWN
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin SecretionNCT01030952 · 2009-12-01
COMPLETED
Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)NCT00858676 · 2009-04-01
UNKNOWN
Acarbose Cardiovascular Evaluation TrialNCT00829660 · 2009-02-17
COMPLETED
Acarbose, Postprandial Hypotension and Type 2 DiabetesNCT02043886 · 2007-06-01
COMPLETED
Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DMNCT00417729 · 2007-01-01
COMPLETED
The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic PatientsNCT00437918 · 2007-01-01
COMPLETED
Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 DiabetesNCT00417950 · 2007-01-01
UNKNOWN
Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 DiabetesNCT00551954 · 2006-07-01
COMPLETED
Acarbose and Secondary Prevention After Coronary StentingNCT00221156 · 2005-05-01
COMPLETED
AI(I)DA Acarbose and the Subclinical InflammationNCT00558883 · 2005-01-01
COMPLETED
Exercise and Acarbose in Type 2 DiabetesNCT01244971 · 2004-01-01
COMPLETED

Conditions being studied

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.